Ezz El Din, M., Salah, R., Kamel, T., Nagy, A. (2022). Evaluation of the Effect of Combination Chemotherapy with Five-day Infusion of Fluorouracil plus Vinorelbine in Pretreated Metastatic Breast Cancer Patients. The Egyptian Journal of Hospital Medicine, 88(1), 2554-2560. doi: 10.21608/ejhm.2022.239189
Mai Ezz El Din; Rasha Salah; Tarek Kamel; Ahmed Nagy. "Evaluation of the Effect of Combination Chemotherapy with Five-day Infusion of Fluorouracil plus Vinorelbine in Pretreated Metastatic Breast Cancer Patients". The Egyptian Journal of Hospital Medicine, 88, 1, 2022, 2554-2560. doi: 10.21608/ejhm.2022.239189
Ezz El Din, M., Salah, R., Kamel, T., Nagy, A. (2022). 'Evaluation of the Effect of Combination Chemotherapy with Five-day Infusion of Fluorouracil plus Vinorelbine in Pretreated Metastatic Breast Cancer Patients', The Egyptian Journal of Hospital Medicine, 88(1), pp. 2554-2560. doi: 10.21608/ejhm.2022.239189
Ezz El Din, M., Salah, R., Kamel, T., Nagy, A. Evaluation of the Effect of Combination Chemotherapy with Five-day Infusion of Fluorouracil plus Vinorelbine in Pretreated Metastatic Breast Cancer Patients. The Egyptian Journal of Hospital Medicine, 2022; 88(1): 2554-2560. doi: 10.21608/ejhm.2022.239189
Evaluation of the Effect of Combination Chemotherapy with Five-day Infusion of Fluorouracil plus Vinorelbine in Pretreated Metastatic Breast Cancer Patients
Background: Continuous infusion (CI) of 5-fluorouracil (5FU) and vinorelbine, individually and in combination, has been proven in several studies to be active and well tolerated for advanced pretreated breast cancer. Objective: This study sought to evaluate the clinical activity and side effects of their combination in pretreated metastatic breast cancer patients. Patients and Methods: This retrospective study collected and analysed the medical records of fifty-four patients who attended El-Salam Oncology Center and Ain Shams University Hospitals, Department of Clinical Oncology during the period from July 2013 to June 2018. Combination chemotherapy received was 5FU 600 mg/m2/d for 5 consecutive days as a CI and vinorelbine 25 mg/m2 on days 1 and 5 as a short intravenous (IV) infusion every 3 weeks. Results: Eleven (20.4%) complete responses, 20 (37%) partial responses and 14 (25.9%) stable disease were documented, accounting for a clinical benefit rate of 83.3%. The median progression free survival was 6.8 months. The median overall survival (mOS) was 25.8 months. Treatment was well tolerated, with grade 3 anemia, febrile neutropenia and stomatitis in 9.3%, 5.6% and 1.9% respectively as the main adverse reactions. Conclusions: This drug combination is active in metastatic previously treated breast cancer patients with an acceptable toxicity profile and continues to be present in the treatment armamentarium in this setting.
Top